A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia

被引:40
作者
Heddle, NM [1 ]
Cook, RJ
Sigouin, C
Slichter, SJ
Murphy, M
Rebulla, P
机构
[1] McMaster Univ, Canadian Blood Serv, Dept Med, Hamilton, ON, Canada
[2] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada
[3] Univ Toronto, Dept Hlth Policy Managmeent & Evaluat, Toronto, ON, Canada
[4] Puget Sound Blood Ctr, Seattle, WA 98104 USA
[5] Univ Washington, Sch Med, Seattle, WA 98195 USA
[6] John Radcliff Headington, Natl Blood Serv Midlands & SW Zone, Oxford, England
[7] Maggiore Hosp, IRCCS, Transfus & Transplant Immunol Ctr, Milan, Italy
关键词
D O I
10.1111/j.1537-2995.2006.00822.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Recently, bleeding has been used in platelet (PLT) trials rather than surrogate outcomes. The purpose of this study was to provide a descriptive summary of data from PLT studies conducted in four countries and exploratory analyses to determine the relationship between bleeding and PLT count. STUDY DESIGN AND METHODS: A descriptive analysis was performed on original data from the Italian trigger study, the US TRAP study, the Canadian febrile reaction study, and a clinical chart review from one hospital site in the United Kingdom. The relationship between bleeding and PLT count was explored with the Italian data. RESULTS: A total of 897 patients with acute leukemia received 10,506 PLT transfusions. Grade 3 or Grade 4 WHO bleeding frequency was 28.1 percent (252/897) but varied by country: Italy, 10.8 percent (27/250); United States, 36.4 percent (217/598); Canada, 18.9 percent (7/37); and the United Kingdom, 8.3 percent (1/12). Grade 1 or Grade 2 bleeding was reported only in the Italian study (46.4%[116/250] and 11.6%[29/250], respectively). The relative rates of WHO Grade 2, 3, or 4 bleeding for PLT counts in the ranges of 0 to 4, 5 to 9, 10 to 14, and 15 to 19 (x10(9)/L) were 8.8, 1.9, 1.8, and 1.2, respectively, compared to those counts within the range of 20 to 29 (x10(9)/L). CONCLUSION: The study provides descriptive data on PLT use and frequency of bleeding. When PLT counts were 0 x 10(9) to 4 x 10(9) per L there was an eightfold increase in bleeding and a twofold risk increase when counts were 5 x 10(9) to 14 x 10(9) per L compared to the 20 x 10(9) to 29 x 10(9) per L reference range. The increased rate of bleeding at low counts occurred despite PLT therapy.
引用
收藏
页码:903 / 911
页数:9
相关论文
共 20 条
[1]   COX REGRESSION-MODEL FOR COUNTING-PROCESSES - A LARGE SAMPLE STUDY [J].
ANDERSEN, PK ;
GILL, RD .
ANNALS OF STATISTICS, 1982, 10 (04) :1100-1120
[2]  
[Anonymous], 2002, STAT MODELS METHODS, DOI DOI 10.1002/9781118033005
[3]   QUANTITATIVE RELATION BETWEEN PLATELET COUNT AND HEMORRHAGE IN PATIENTS WITH ACUTE LEUKEMIA [J].
GAYDOS, LA ;
MANTEL, N ;
FREIREICH, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1962, 266 (18) :905-&
[4]  
GilFernandez JJ, 1996, BONE MARROW TRANSPL, V18, P931
[5]   SAFETY OF STRINGENT PROPHYLACTIC PLATELET TRANSFUSION POLICY FOR PATIENTS WITH ACUTE-LEUKEMIA [J].
GMUR, J ;
BURGER, J ;
SCHANZ, U ;
FEHR, J ;
SCHAFFNER, A .
LANCET, 1991, 338 (8777) :1223-1226
[6]   Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/mu L versus 20,000/mu L [J].
Heckman, KD ;
Weiner, GJ ;
Davis, CS ;
Strauss, RG ;
Jones, MP ;
Burns, CP .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1143-1149
[7]   A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets [J].
Heddle, NM ;
Blajchman, MA ;
Meyer, RM ;
Lipton, JH ;
Walker, IR ;
Sher, GD ;
Constantini, LA ;
Patterson, B ;
Roberts, RS ;
Thorpe, KE ;
Levine, MN .
TRANSFUSION, 2002, 42 (05) :556-566
[8]   Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies [J].
Heddle, NM ;
Cook, RJ ;
Webert, KE ;
Sigouin, C ;
Rebulla, P .
TRANSFUSION, 2003, 43 (06) :742-752
[9]   Lowering the prophylactic platelet transfusion threshold: A prospective analysis [J].
Lawrence, JB ;
Yomtovian, RA ;
Hammons, T ;
Masarik, SR ;
Chongkolwatana, V ;
Creger, RJ ;
Manka, A ;
Lazarus, HM .
LEUKEMIA & LYMPHOMA, 2001, 41 (1-2) :67-76
[10]  
McFarland J, 1997, NEW ENGL J MED, V337, P1861